Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 54: 240-248, 2008; 10.1373/clinchem.2007.097402
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weykamp, C.
Right arrow Articles by Siebelder, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weykamp, C.
Right arrow Articles by Siebelder, C.
(Clinical Chemistry. 2008;54:240-248.)
© 2008 American Association for Clinical Chemistry, Inc.


Special Reports

The IFCC Reference Measurement System for HbA1c: A 6-Year Progress Report

Cas Weykamp1,a, W Garry John2, Andrea Mosca3, Tadao Hoshino4, Randie Little5, Jan-Olof Jeppsson6, Ian Goodall7, Kor Miedema8, Gary Myers9, Hans Reinauer10, David B. Sacks11, Robbert Slingerland8 and Carla Siebelder1

1 Queen Beatrix Hospital, Winterswijk, The Netherlands (IFCC-network coordinator); 2 Norfolk and Norwich University Hospital, and School of Medicine, Health Policy and Practice, UEA, Norwich, UK; 3 Centro Interdipartimentale per la Riferibilità Metrologica in Medicina di Laboratorio (CIRME), Università degli Studi di Milano, Milano, Italy; 4 Institute of Biopathological Medicine, Kanagawa, Japan (JDS/JSCC network coordinator); 5 University of Missouri School of Medicine, Columbia, MO (NGSP network coordinator); 6 Malmoe University Hospital, Malmoe, Sweden (Coordinator Reference System Sweden); 7 Austin Pathology, Austin Health, Heidelberg, Australia; 8 Isala Klinieken, Zwolle, the Netherlands; 9 Center for Disease Control and Prevention, Atlanta, GA; 10 INSTAND e.V., Duesseldorf, Germany; 11 Brigham and Women’s Hospital and Harvard Medical School, Boston, MA.

aAddress correspondence to this author at: Queen Beatrix Hospital, Beatrixpark 1, 7101 BN Winterswijk, the Netherlands. Fax +31 543 524265; e-mail c.w.weykamp{at}skbwinterswijk.nl.

Background: The IFCC Reference Measurement System for hemoglobin (Hb)A1c (IFCC-RM) has been developed within the framework of metrologic traceability and is embedded in a network of 14 reference laboratories. This paper describes the outcome of 12 intercomparison studies (periodic evaluations to control essential elements of the IFCC-RM).

Methods: Each study included: unknown samples (to test individual network laboratories); known samples (controls); recently manufactured calibrators (to check calculated assigned value); stored calibrators (to test stability) and a calibration-set (to calibrate the IFCC-RM). The unknown samples are measured by use of the IFCC-RM and the designated comparison methods [DCMs; the National Glycohemoglobin Standardization Program (NGSP) in the US, Japanese Diabetes Society/Japanese Society for Clinical Chemistry (JDS/JSCC) in Japan, and Mono-S in Sweden] are used to investigate the stability of the Master Equation (ME), the relationship between IFCC-RM and DCMs.

Results: A total of 105 IFCC-RM data sets were evaluated: 95 were approved, 5 were not, and for 5 no data were submitted. Trend analysis of the MEs, expressed as change in percentage HbA1c per year, revealed 0.000% (NGSP, not significant), –0.030%, (JDS/JSCC; significant) and –0.016% (Mono-S; not significant). Evaluation of long-term performance revealed no systematic change over time; 2 laboratories showed significant bias, 1 poor reproducibility. The mean HbA1c determined by laboratories performing mass spectrometry (MS) was the same as the mean determined by laboratories using capillary electrophoresis (CE), but the reproducibility at laboratories using CE was better. One batch of new calibrators was not approved. All stored calibrators were stable.

Conclusion: A sound reference system is in place to ensure continuity and stability of the analytical anchor for HbA1c.




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
A. Geistanger, S. Arends, C. Berding, T. Hoshino, J.-O. Jeppsson, R. Little, C. Siebelder, C. Weykamp, and on behalf of the IFCC Working Group on Standardiza
Statistical Methods for Monitoring the Relationship between the IFCC Reference Measurement Procedure for Hemoglobin A1c and the Designated Comparison Methods in the United States, Japan, and Sweden
Clin. Chem., August 1, 2008; 54(8): 1379 - 1385.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.